S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)

AVITA Medical (RCEL) Stock Price, News & Analysis

$16.03
-0.47 (-2.85%)
(As of 04:00 PM ET)
Today's Range
$15.82
$16.65
50-Day Range
$13.91
$18.31
52-Week Range
$9.16
$21.70
Volume
126,169 shs
Average Volume
167,014 shs
Market Capitalization
$412.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.80

AVITA Medical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
73.4% Upside
$27.80 Price Target
Short Interest
Healthy
2.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.15) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

816th out of 938 stocks

Surgical & Medical Instruments Industry

86th out of 97 stocks

RCEL stock logo

About AVITA Medical Stock (NASDAQ:RCEL)

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

RCEL Stock Price History

RCEL Stock News Headlines

RCEL Oct 2024 17.500 put
RCEL Apr 2024 22.500 put
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
BRIEF-Seatrium Limited Says FY Revenue S$7.3 Bln
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Q4 2023 Earnings Preview
RCEL Mar 2024 15.000 call
AVITA Medical: Q3 Earnings Insights
See More Headlines
Receive RCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVITA Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:RCEL
Fax
N/A
Employees
207
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$27.80
High Stock Price Target
$40.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+68.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-35,380,000.00
Pretax Margin
-70.43%

Debt

Sales & Book Value

Annual Sales
$50.14 million
Book Value
$1.92 per share

Miscellaneous

Free Float
25,203,000
Market Cap
$424.22 million
Optionable
Optionable
Beta
1.39

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. James M. Corbett (Age 66)
    CEO, President & Executive Director
    Comp: $1.16M
  • Mr. David O'Toole (Age 65)
    Chief Financial Officer
    Comp: $574.64k
  • Ms. Donna Shiroma (Age 61)
    General Counsel, Chief Compliance Officer & Secretary
    Comp: $688.6k
  • Mr. David Fencil
    Senior Vice President of Global Operations
  • Dr. Katie Bush Ph.D.
    Senior Vice President of Scientific & Medical Affairs
  • Ms. Jessica Ekeberg
    Investor Relations Executive
  • Ms. Debbie Garner
    Senior Vice President of Global Marketing & Strategy
  • Mr. Rob Hall
    Senior Vice President of Human Resources
  • Mr. Terry Bromley
    Senior Vice President of Global Sales
  • Dr. Niraj Doshi J.D.
    P.M.P., Ph.D., Senior Vice President of Product Development & Program Management

RCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell AVITA Medical stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AVITA Medical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCEL shares.
View RCEL analyst ratings
or view top-rated stocks.

What is AVITA Medical's stock price target for 2024?

5 brokerages have issued 1 year price objectives for AVITA Medical's stock. Their RCEL share price targets range from $21.00 to $40.00. On average, they predict the company's share price to reach $27.80 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price.
View analysts price targets for RCEL
or view top-rated stocks among Wall Street analysts.

How have RCEL shares performed in 2024?

AVITA Medical's stock was trading at $13.72 at the start of the year. Since then, RCEL shares have increased by 16.8% and is now trading at $16.03.
View the best growth stocks for 2024 here
.

When is AVITA Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RCEL earnings forecast
.

How were AVITA Medical's earnings last quarter?

AVITA Medical, Inc. (NASDAQ:RCEL) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.06. The business earned $14.20 million during the quarter, compared to analyst estimates of $14.10 million. AVITA Medical had a negative trailing twelve-month return on equity of 54.80% and a negative net margin of 70.56%.

What guidance has AVITA Medical issued on next quarter's earnings?

AVITA Medical issued an update on its first quarter 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.8 million-$15.6 million, compared to the consensus revenue estimate of $15.8 million.

What other stocks do shareholders of AVITA Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVITA Medical investors own include NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), PayPal (PYPL), Twilio (TWLO), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Livongo Health (LVGO).

Who are AVITA Medical's major shareholders?

AVITA Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.45%), Vanguard Group Inc. (5.42%), Pura Vida Investments LLC (1.41%), Northern Trust Corp (0.88%), Dimensional Fund Advisors LP (0.37%) and 1492 Capital Management LLC (0.28%). Insiders that own company stock include David D O'toole, Donna Shiroma, James Corbett, Jeremy Curnock Cook, Michael S Perry, Michael S Perry and Suzanne Crowe.
View institutional ownership trends
.

How do I buy shares of AVITA Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCEL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners